2018
DOI: 10.1002/advs.201800155
|View full text |Cite
|
Sign up to set email alerts
|

NIR‐Activated Polydopamine‐Coated Carrier‐Free “Nanobomb” for In Situ On‐Demand Drug Release

Abstract: Carrier‐free nanoparticles with high drug loading have attracted increasing attention; however, in situ on‐demand drug release remains a challenge. Here, a novel near‐infrared (NIR) laser‐induced blasting carrier‐free nanodrug delivery system is designed and fabricated by coating doxorubicin (DOX) nanoparticles (DNPs) with a polydopamine film (PDA) that would prolong the blood circulation time of DNPs and avoid the preleakage of the DOX during blood circulation. Meanwhile, the NH4HCO3 is introduced to trigger … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
80
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 126 publications
(91 citation statements)
references
References 41 publications
2
80
0
Order By: Relevance
“…The absorption peak at 1,500 cm −1 proves that the -C=C-was contained in FMPBs. The broad absorption peak at the range of 3,200-3,600 cm −1 is the N-H stretching vibration peak, proving the existence of PDA molecules in FMPBs (Li et al, 2018;Maziukiewicz et al, 2019). The absorption peak of 1,100 cm −1 is regarded as the deformation vibration peak of -OH.…”
Section: Synthesis and Characterizations Of Fmpbsmentioning
confidence: 92%
See 2 more Smart Citations
“…The absorption peak at 1,500 cm −1 proves that the -C=C-was contained in FMPBs. The broad absorption peak at the range of 3,200-3,600 cm −1 is the N-H stretching vibration peak, proving the existence of PDA molecules in FMPBs (Li et al, 2018;Maziukiewicz et al, 2019). The absorption peak of 1,100 cm −1 is regarded as the deformation vibration peak of -OH.…”
Section: Synthesis and Characterizations Of Fmpbsmentioning
confidence: 92%
“…However, up to now, only a limited number of nanocarriers have been successfully used in the clinical treatment of cancer (Bulbake et al, 2017), because many nanocarriers either have a low drug-carrying capacity or have difficulty to efficiently reach the tumor site (Jia et al, 2015). The ideal nanocarrier should have a high drug loading efficiency and a suitable size, which can accurately transport the drug to the target area in the body for controlled release (Liu et al, 2014;Bose et al, 2016;Li et al, 2018).…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…39 The distinct absorption peak of DOX is observed in the spectrum of ZIF-8/DOX and dramatically weakened in DOX@HMONs-PDA ( Figure S2), which was probably due to the quenching effect of PDA. 40 Moreover, the supernatant solution of ZIF-8/DMPP shows no absorption peaks, indicating the DOX is effectively sealed in the framework. Meanwhile, a high drugloading content of 18.9% is obtained by this one-pot method.…”
Section: Drug Release Of Zif-8/dmppmentioning
confidence: 99%
“…The NIR‐activated strategy had been applied for being triggered a series of reactions for drug delivery on demand in situ. For example, a polydopamine film (PDA) was formed to coat DOX and NH 4 HCO 3 (M. Li et al, ). The NH 4 HCO 3 triggered in situ “bomb‐like” release of DOX, because of the burst production of gases including ammonia (NH 3 ) and carbon dioxide (CO 2 ).…”
Section: Physical‐responsive Nanomedicinementioning
confidence: 99%